Announcing the NCI Formulary, the Jan. 13 issue of The Cancer Letter includes comments suggesting the road to new therapies will now get “easier” and other comments indicated that industry and/or NCI collaborators will “not provide support other than drug access”.
LUNGevity announced a request for applications for translational research for career development awards that will be granted in 2017.
ONCURIOUS NV, an emerging oncology company focused on the development of innovative orphan drugs for the treatment of pediatric tumors, announced that the European Commission has confirmed the orphan drug designation for TB-403 for medulloblastoma.
Richard Goldberg, a gastrointestinal cancer expert, was named the new director of the WVU Cancer Institute.
Justin Klamerus was appointed to president of the Barbara Ann Karmanos Cancer Hospital, the clinical operation of Karmanos Cancer Institute.
Maria Werner-Wasik was named executive vice chair for radiation oncology integration and the Walter Curran Professor of Radiation Oncology.
Northwell Health announced collaboration with Indivumed to speed the advance of precision cancer research.
Tempus, a technology company focused on helping doctors personalize cancer care, and University Hospitals Seidman Cancer Center joined together to improve research and healthcare by making genomic data, advanced molecular analysis and clinical decision support tools available to the hospital's researchers, physicians and healthcare providers.
The Society of Thoracic Surgeons released the first publicly accessible national report of outcomes from lobectomy, a lung cancer procedure that removes a portion of the lung.
A phase II study of abemaciclib, a cyclin-dependent kinase 4 and CDK 6 inhibitor, met its primary endpoint of reducing expression of Ki67, a biomarker of cell proliferation, after two weeks of treatment.
